TY - JOUR AU - Grande, E AU - Alonso-Gordoa, T AU - Reig, O AU - Esteban, E AU - Castellano, D AU - Garcia-Del-Muro, X AU - Mendez, M J AU - Garcia-Donas, J AU - Gonzalez Rodriguez, M AU - Arranz-Arija, J A AU - Lopez-Criado, P AU - Molina-Cerrillo, J AU - Mellado, B AU - Alvarez-Fernandez, C AU - De Velasco, G AU - Cuellar-Rivas, M A AU - Rodriguez-Alonso, R M AU - Rodriguez-Moreno, J F AU - Suarez-Rodriguez, C PY - 2022 DO - 10.1016/j.esmoop.2022.100463 UR - http://hdl.handle.net/10668/22214 T2 - ESMO open AB - The INMUNOSUN trial had the objective of prospectively evaluating the efficacy and safety of sunitinib as a pure second-line treatment in patients with metastatic renal cell carcinoma (mRCC) who have progressed to first-line immune checkpoint... LA - en PB - Elsevier KW - Immune checkpoint inhibitors KW - Metastatic renal carcinoma KW - Second-line treatment KW - Sunitinib KW - Carcinoma, Renal Cell KW - Female KW - Humans KW - Indoles KW - Kidney Neoplasms KW - Male KW - Prospective Studies KW - Sunitinib TI - Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. TY - research article VL - 7 ER -